Understanding the molecular basis of vitiligo - a systematic review
DOI:
https://doi.org/10.12775/JEHS.2023.44.01.019Keywords
nrf2, vitiligo, etiology, leptin, pathogenesis, reactive oxygen species, oxidative stressAbstract
Introduction: Vitiligo is a systemic, chronic, hypopigmented dermatosis
of unclear background. The disease is characterized by the selective loss or dysfunction of melanocytes. As a result we can observe various, well and non-squamous depigmentation areas of different size and shape. The pathogenesis of vitiligo is not fully understood, however, the current view is that the etiopathology of this disease is complex
Purpose of the study: Current treatment models are often nonspecific, so it is important to understand the pathomechanism that can help with vitiligo lesions. It will also sensitize researchers to the search for new therapeutic options
Material and methods: Collected scientific articles and guidelines available online of high substantive value. Expressions that were searched in databases: vitiligo, etiology, leptin, pathogenesis, reactive oxygen species, oxidative stress
Results and conclusions: The scientific papers and researches cited in the article show that the major role is played by cellular stress and reactive oxygen forms, secondary inflammation or environmental factors. Cellular stress activates autoimmune and autoinflammatory mechanisms that destroy pigment cells. Therefore, there are probably even more mechanisms contributing to the development of vitiligo.
Illness can affect the patient 's quality of life. In recent years, there has been significant progress in understanding the pathogenesis of vitiligo. Effective treatment of vitiligo remains a difficult challenge for both scientists and dermatologists.
References
Rafal Czajkowski , Waldemar Placek , Iwona Flisiak , Dorota Krasowska , Joanna Maj , Mariola Marchlewicz , Adam Reich , Hanna Wolska , Lidia Rudnicka, Bielactwo nabyte. Rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego dostęp: 06.06.2023r
Marchioro HZ, Silva de Castro CC, Fava VM, Sakiyama PH, Dellatorre G, Miot HA. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022 Jul-Aug;97(4):478-490. doi: 10.1016/j.abd.2021.09.008. Epub 2022 May 25. PMID: 35643735; PMCID: PMC9263675. dostęp 1.07.2023r
https://www.mp.pl/pacjent/dermatologia/choroby/chorobyskory/167718,bielactwo-nabyte dostęp 29.06.2023r
Julien Seneschal, Katia Boniface, Andrea D’Arino, Mauro Picardo, An update on Vitiligo pathogenesis,
First published: 05 December 2020 doi.org/10.1111/pcmr.12949 dostęp 1.07.2023r
Chang, W.-L.; Ko, C.-H. The Role of Oxidative Stress in Vitiligo: An Update on Its Pathogenesis and Therapeutic Implications. Cells 2023, 12, 936. https://doi.org/10.3390/cells12060936 dostęp 9.07.2023r
https://podyplomie.pl/dermatologia/29638,bielactwo-od-teorii-do-praktyki-klinicznej dostęp: 2.07.2023r
Diotallevi, F.; Gioacchini, H.; De Simoni, E.; Marani, A.; Candelora, M.; Paolinelli, M.; Molinelli, E.; Offidani, A.; Simonetti, O. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. Int. J. Mol. Sci. 2023, 24, 4910. https://doi.org/10.3390/ijms24054910
Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. Int J Mol Sci. 2023 Jun 5;24(11):9749. doi: 10.3390/ijms24119749. PMID: 37298700; PMCID: PMC10253679. dostęp: 3.07.2023r
Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. Int J Mol Sci. 2023 Jun 5;24(11):9749. doi: 10.3390/ijms24119749. PMID: 37298700; PMCID: PMC10253679. dostęp: 3.07.2023r
Alicja Konieczna , Andrzej Winnicki , Jerzy Krysiński, Nowe perspektywy leczenia bielactwa nabytego
Katedra Technologii Postaci Leku, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu, Polska Farmacja Polska, ISSN 2544-8552, dostęp: 30.06.2023
Ben Ahmed M, Zaraa I, Rekik R, Elbeldi-Ferchiou A, Kourda N, Belhadj Hmida N, Abdeladhim M, Karoui O, Ben Osman A, Mokni M, Louzir H. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res. 2012 Jan;25(1):99-109. doi: 10.1111/j.1755-148X.2011.00920.x. Epub 2011 Oct 25. PMID: 21985183. dostęp: 3.07.2023r
Helena Zenedin Marchioro, Caio César Silva de Castro, Vinicius Medeiros Fava, Paula Hitomi Sakiyama, Gerson Dellatorre, Hélio Amante Miot,
Update on the pathogenesis of vitiligo, Anais Brasileiros de Dermatologia, Volume 97, Issue 4,2022,
Pages 478-490,ISSN 0365-0596, https://doi.org/10.1016/j.abd.2021.09.008 dostęp: 7.07.2023r
https://www.sciencedirect.com/science/article/pii/S0365059622000654?via%3Dihub#bib0455
Baird, L.; Yamamoto, M. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. Mol. Cell. Biol. 2020, 40, e00099-20 dostęp: 8.07.2023r
Bergqvist, C., & Ezzedine, K. (2021). Vitiligo: A focus on pathogenesis and its therapeutic implications. The Journal of Dermatology, 48(3), 252–270. doi:10.1111/1346-8138.15743 dostęp: 15.07.2023r
El-Hawary M, El-Tahlawi S, Ibrahim S, El Ansary M, Mogawer RM. Possible enigmatic link between serum leptin and vitiligo with its metabolic derangements: A comparative controlled study. J Cosmet Dermatol. 2022 Jul;21(7):2971-2976. doi: 10.1111/jocd.14490. Epub 2021 Oct 3. PMID: 34601796. dostęp: 7.07.2023r
Dragoni F, Conti R, Cazzaniga S, Colucci R, Pisaneschi L, Naldi L, et al. No association between vitiligo and obesity: a case-control study. Med principles Pract (2017) 26(5):421–6. doi: 10.1159/000481436
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1158883/full
Feng Y, Lu Y. Advances in vitiligo: Update on therapeutic targets. Front Immunol. 2022 Aug 31;13:986918. doi: 10.3389/fimmu.2022.986918. PMID: 36119071; PMCID: PMC9471423. Dostęp 09.07.2023r
Mineiro dos Santos Garrett, N.F.; Carvalho da Costa, A.C.; Barros Ferreira, E.; Damiani, G.; Diniz dos Reis, P.E.; Inocêncio Vasques, C. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLoS ONE 2021,dostęp 12.07.2023r
Frączek A, Kasprowicz-Furmańczyk M, Placek W, Owczarczyk-Saczonek A. Surgical Treatment of Vitiligo. International Journal of Environmental Research and Public Health. 2022; 19(8):4812. https://doi.org/10.3390/ijerph19084812
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. Erratum in: J Am Acad Dermatol. 2023 Apr 6;: PMID: 36370907. Dostęp 12.07.2023r
Lin X, Meng X, Song Z, Lin J. Nuclear factor erythroid 2-related factor 2 (Nrf2) as a potential therapeutic target for vitiligo. Arch Biochem Biophys. 2020 Dec 15;696:108670. doi: 10.1016/j.abb.2020.108670. Epub 2020 Nov 10. PMID: 33186606. Dostęp 12.07.2023r
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Magdalena Osuch, Magdalena Gaik, Rafał Bogacz, Ewa Uram, Justyna Woźniak, Karol Womperski, Inga Magda
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 389
Number of citations: 0